Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Migraine

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Migraine

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Arteaus Therapeutics; Eli Lilly and Company

    • Most Recent Events

    • 11 Jun 2017 Results (n=858) of pooled analysis assessing hepatic safety using patient data from three phase 2 trials (NCT02163993 and NCT01625988), presented at the 59th Annual Scientific Meeting of the American Headache Society
    • 28 Apr 2017 Results (n=858) of pooled analysis assessing hepatic safety using patient data from three phase 2 trials (NCT02163993 and NCT01625988), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 20 Apr 2017 Results of a Post-Hoc Analysis from this trial will be presented at the American Academy of Neurology (AAN) annual meeting 2017, as reported in an Eli Lilly and Company media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top